CIBUS INC Stock Price, News & Analysis

Ecuador's Ministry of Agriculture and Livestock has determined that Cibus' (CBUS) herbicide tolerance Rice traits (HT1 and HT3) are equivalent to conventional breeding methods. This regulatory approval means these traits will be subject to standard seed regulations rather than strict GMO restrictions in Ecuador.

The traits, developed using Cibus' Rapid Trait Development System™ (RTDS®) technology, create targeted genetic changes without introducing foreign genetic material. Cibus plans to commercialize these traits in Latin American markets through a partnership with Interoc, focusing on providing improved weed management solutions for rice growers.

Cibus (Nasdaq: CBUS), a leading agricultural biotechnology company specializing in proprietary gene editing technologies for plant trait development in seeds, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025 after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and company updates. Participants can join via phone using U.S. (+1-833-316-1983) or International (+1-785-838-9310) numbers with conference ID 'CIBUS' or 24287.

A replay will be available through May 22, 2025, and the webcast with slides will be accessible on the company's investor website for 90 days after the event.

Cibus (NASDAQ: CBUS) announced that the USDA-APHIS has designated two of its canola disease resistance trait products as non-regulated. These traits, developed using Cibus' Rapid Trait Development System™ (RTDS®), create targeted genetic changes without introducing foreign genetic material.

The designation allows Cibus to proceed with product development without restrictions in the U.S. The company's Sclerotinia resistance trait in canola provides multiple modes of action to combat white mold, a fungal pathogen that can reduce canola yields by 7-15%, with losses up to 50% per infected plant.

This development aligns with global regulatory modernization trends, including recent advancement in the European Union where member states endorsed regulations for New Genomic Techniques (NGTs), allowing certain gene-edited products to be regulated similarly to conventional varieties.

Cibus (NASDAQ: CBUS) reported its Q4 2024 financial results and business updates. The company achieved significant milestones in gene editing technology development, including:

Key developments include the EU's advancement of New Genomic Techniques legislation on March 14, 2025, and California Rice Commission's historic approval for gene-edited rice field trials. The company affirmed strategic collaborations with Albaugh and RTDC for herbicide tolerance traits in rice, while making progress in Sclerotinia resistance with a fourth mode of action in Canola.

Financial highlights for Q4 2024:

• Cash position: $14.4 million as of December 31, 2024
• R&D expenses: $12.4 million, down from $14.2 million year-ago
• Net loss: $25.8 million ($0.87 per share)

The company completed a $22.6 million registered direct offering in January 2025, expecting to fund operations into late Q3 2025. Cibus implemented cost-saving initiatives targeting $10 million in annual savings and a 20% reduction in monthly cash use.

Cibus (Nasdaq: CBUS) welcomes major progress in EU regulation of New Genomic Techniques (NGTs) as EU member states endorse the Council's negotiating mandate on March 14th, 2025. The legislation aims to regulate plants obtained through NGTs, including gene editing, to promote sustainable agriculture and food security.

The proposal introduces an 'NGT-1' category for 'conventional-like' products that could occur naturally or through conventional breeding. These products would be exempt from GMO legislation and labeling requirements, aligning EU policy with global trading partners including North and South America, UK, India, Australia, and Japan.

The Council can now enter trilogue discussions with the EU Parliament and European Commission to finalize the legislation. Cibus's RTDS® technologies produce improved crop varieties that qualify as 'conventional-like' under the proposal, focusing on rapeseed genetics for reduced seed loss, increased disease resistance, and enhanced nutrient use efficiency.

Cibus (Nasdaq: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for plant trait development in seeds, has scheduled its fourth quarter 2024 financial results announcement for March 20, 2025, after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and company updates. U.S. participants can dial +1-877-300-8521, while international participants can use +1-412-317-6026.

A replay will be available until April 3, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with passcode 10196898. The webcast and slides will be available on the company's investor website for 90 days after the event.

Cibus (NASDAQ: CBUS) announced promising results from controlled environment testing of its third mode of action (MOA) for Sclerotinia resistance trait in Canola. The company's proprietary Rapid Trait Development System™ (RTDS®) technology enables the Trait Machine™, a semi-automated precision breeding system.

The company has completed edits in four MOAs for Sclerotinia resistance in Canola, with ongoing field tests for two of them. Management expects to complete field and/or greenhouse tests on all four MOAs by year-end 2025. The development aims to help farmers preserve crop yields and reduce fungicide usage.

This novel approach using gene editing demonstrates potential for developing durable resistance to complex diseases more quickly compared to conventional breeding methods. The company anticipates that these traits could extend to other crops like Soybean, addressing challenges posed by climate-driven changes in crop diseases and their geographic distribution.

Cibus (NASDAQ: CBUS) announced significant leadership changes as part of its succession strategy. CEO Rory Riggs has stepped down, with President and COO Peter Beetham assuming the role of Interim CEO. Riggs will continue as Chairman of the Board of Directors, while Beetham maintains his director position.

The company, which specializes in developing and licensing plant traits to seed companies for royalties, will initiate a search for a permanent CEO, considering both internal and external candidates. Greg Gocal will continue as Chief Scientific Officer.

This transition comes at a pivotal moment as Cibus evolves from an agricultural trait development company to a commercial trait company, leveraging its proprietary Rapid Trait Development System™ (RTDS®) gene editing process. The Board expressed confidence in the leadership team's ability to execute commercial priorities during this transition period.

Cibus (NASDAQ: CBUS) has issued a significant correction regarding previously reported rice gene editing conversion rates. The company acknowledged that the previously announced rates of 10-25% in Rice have not been reconfirmed, citing high variability in conversion rate data from subsequent experiments.

Despite this setback, Cibus continues to advance its oligonucleotide directed mutagenesis (ODM) editing technologies to improve editing conversion rates across various crops. The company maintains confidence in its Rapid Trait Development System™ (RTDS®) to meet customer requirements for trait editing in their germplasm through a time-bound and predictable process.